Trialbee, a patient matching and enrolment platform, and uMotif, a patient-centric data capture provider, are partnering hoping to improve the patient experience and improve trial accessibility globally. The companies’ integrated platforms simplify trial activities from initial awareness through enrollment and data collection during study conduct and close-out.
Patients are digitally matched to study protocols via Trialbee HIVE. Qualified, study-ready patients are then consented at-site or remotely through the Trialbee platform, which is integrated with uMotif’s application. Once enrolled, patients use the engaging uMotif app to capture large volumes of ePRO, eDiary and symptom data in real-time throughout the duration of a trial. Patients are empowered to manage and collect their data in an application, while sponsors receive an understanding of patient symptoms and behavior.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.